Investors / United Kingdom / Medicxi
Medicxi
Venture capital · London, United Kingdom · Europe
Medicxi is a European investment firm focused on the life sciences sector, established in 2016 by the former Index Ventures life sciences team. It creates, invests in and supports biotech companies along the drug development continuum, from discovery through pivotal studies and registration.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechtherapeuticsdrug discoveryasset-centricclinical development
Your fit with Medicxi
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsMedicxi lists 5 checked portfolio companies on its own site and is named in 6 funding rounds, 1 of them as lead. Its most frequent entry is Series B, 80% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 60% of its companies are based in United States. It invests most often alongside 3B Future Health Fund, Atlantic and Atlas Venture.
Counts come from funding rounds that name Medicxi, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 80% |
| Growth | 20% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 4 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 4th | 5 companies |
| Recent activity | 86th | 5 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| 3B Future Health Fund | 1 |
| Atlantic | 1 |
| Atlas Venture | 1 |
| Avoro Capital Advisors | 1 |
| Axil Capital | 1 |
| Droia Ventures | 1 |
| Forbion | 1 |
| HSG | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with 3B Future Health Fund
Compare Medicxi head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
as stated on its siteRecent portfolio activity
when companies last raised with Medicxi| Date | Company | Stage |
|---|---|---|
| 11 Aug 2026 | Series B | |
| 7 Jul 2026 | Series C+ Led | |
| 10 Jun 2026 | Series B | |
| 19 Feb 2026 | Series B | |
| 9 Dec 2025 | Series B | |
| 22 May 2025 | Series C+ |
Round details for Medicxi
Amounts, full round histories and every co-investor in Medicxi's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
5 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Altesa BioSciences is developing a medicine to treat rhinovirus infections in chronic lung diseases such as COPD and asthma | Healthcare & Biotech | Feb 2026Series B | Funding round | |
| D3 Bio develops innovative medicines for patients in need worldwide, focusing on oncology and immunology | Healthcare & Biotech | Dec 2025Series B | Funding round | |
| Ethyreal Bio is dedicated to improving the lives of people with Thyroid Eye Disease and Graves’ Disease | Healthcare & Biotech | Jun 2026Series B | Funding round | |
| Fore Biotherapeutics develops targeted therapies for treating cancers. | Healthcare & Biotech | May 2025Series C+ · 2 rounds | Funding round | |
| Vaderis Therapeutics is a biotech company that aims to bring breakthrough therapies to people with HHT and other rare vascular diseases. | Healthcare & Biotech | Aug 2026Series B | Funding round |
About this data
site last read 13 Nov 2026- Site
- medicxi.com
- Last read
- 13 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 22 May 2025
- Companies checked
- 5
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Medicxi's profile as data
Pull Medicxi's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/medicxi.com
# also
GET /v1/firms/medicxi.com/portfolio
GET /v1/firms/medicxi.com/coinvestors
GET /v1/firms/medicxi.com/news